BRNS – barinthus biotherapeutics plc - american depositary shares (US:NASDAQ)
Stock Stats
News
Barinthus Biotherapeutics (NASDAQ:BRNS) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
Form 425 Barinthus Biotherapeutic Filed by: Barinthus Biotherapeutics plc.
Form 8-K Barinthus Biotherapeutic For: Feb 23
Form 8-K Barinthus Biotherapeutic For: Dec 30
Form 8-K Barinthus Biotherapeutic For: Dec 10
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.